Alvogen Reshaped By A Year Of Change
Group Positioned For Future By Sale Of CEE Business And Adalvo B2B Rebranding
After a year that has seen Alvogen divest its central and eastern Europe business to Zentiva and rebrand its B2B unit as Adalvo, the group has also demonstrated the resilience of its supply chain in the face of upheaval caused by the coronavirus pandemic, chairman and CEO Robert Wessman tells Generics Bulletin in the second part of an exclusive interview.
You may also be interested in...
With “many pipeline products coming to the market in the next two years,” Alvogen’s US operation has raised fresh capital via a share issue to Aztiq Pharma, the private equity fund led by Alvogen CEO Robert Wessman.
Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.
A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.